Conclusion
The mixing of OXY injection and TXA products for co-administration with
IV infusion fluids should be avoided until the exact nature of the
interaction and its implications for quality-assured and
non-quality-assured products are understood. Further investigation is
urgently needed to characterise the underlying mechanisms leading to the
observed phenomena and, as appropriate, determine mitigation strategies.